Kite Pharma, Inc.

(%) Date:

Kite Pharma, Inc.

Kite Pharma: NHS Analysis Determines a £530K Price Tag Reasonable for CAR T Therapy

The study was conducted for young ALL and determined a price of £530K ($649K) was justified

Canaccord on Kite Pharma Inc (KITE)

Canaccord believes the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit

Stifel Downgraded Kite Pharma Inc (KITE) to Hold on Valuation in Front of Complex Launch

After the impressive run up in Kite Pharma Inc shares, Stifel downgraded the stock to Hold

Kite Pharma Inc. (KITE) Should Fly Higher With KITE-APP

RBC Capital Markets reiterates its Outperform, Speculative Risk, and built an interactive KITE-APP which suggests even conservative patients/site supports strong launch potential